Composition for regulating blood sugar

Abstract

The present invention provides a composition for regulating blood sugar. The composition comprises at least one yellow pigment extracted from a red mold product, wherein the said yellow pigment is Monascin, Ankaflavin, or combination of Monascin and Ankaflavin. Moreover, results of a variety of animal experiments have proved that this blood sugar regulating composition indeed possess the functionalities of: lowering Hyperglycemia induced by high energy diet, alleviating ROS and inflammatory caused by the Hyperglycemia, reduce AST and ALT value of liver as well as sarcosine value of kidney.

Description

BACKGROUND OF THE INVENTION[0001]1. Field of the Invention[0002]The present invention relates to the technology field of medically-used composition, and more particularly to a composition for regulating blood sugar.[0003]2. Description of the Prior Art[0004]American Diabetes Association (FDA) has published the way to judge whether a person suffers from a diabetes mellitus (DM) or not. When the concentration of fasting blood glucose (GLU-AC) of the person is higher than 126 mg / dL or the concentration of 2 hours postprandial blood glucose (2hPBG) of the person is higher than 200 mg / dL, the person is diagnosed with diabetes mellitus. On the other hand, the person is diagnosed with Impaired Glucose Tolerance (IGT) when the GLU-AC value is measured to fall in a range between 100 mg / dL and 126 mg / dL or the 2hPBG value falls in another one range between 140 mg / dL and 200 mg / dL. IGT means that blood glucose is raised beyond normal levels, but not high enough to warrant a diabetes diagnosis....

AI Technical Summary

Benefits of technology

The patent is about a new product that helps regulate blood sugar. It contains a yellow pigment called Monascin or Ankaflavin, which are found in a type of mold. These pigments have been tested on animals and have shown promising results in lowering high blood sugar, reducing inflammation and damage to organs, and improving kidney and liver function. The patent aims to offer a natural and effective solution for people with blood sugar regulation issues.

Problems solved by technology

IGT means that blood glucose is raised beyond normal levels, but not high enough to warrant a diabetes diagnosis.

However, all the above-mentioned blood sugar reducing drugs have side-effects with varying severity, such as diarrhea, anorexia, nausea, and fatal lactic acidosis.

However, over-activation of PPARγ drives the unwanted and often unacceptable side effects associated with the currently-approved insulin sensitizers, such as edema, weight gain, congestive heart failure, hepatotoxicity.

Images